About: Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic
Creator	Bex, Axel Bossi, Alberto Catto, James Gillessen, Silke Kamat, Ashish Karnes, R Klaassen, Zachary Marandino, Laura Morgan, Todd Mottet, Nicolas Necchi, Andrea Novara, Giacomo Powles, Thomas Roupret, Morgan Wallis, Christopher
source	Elsevier; Medline; PMC
abstract	Abstract Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. Objective To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage. Evidence acquisition A collaborative review using literature published as of April 2, 2020. Evidence synthesis Patients with low-grade non–muscle-invasive bladder cancer are unlikely to suffer from a 3–6-month delay. Patients with muscle-invasive bladder cancer are at risk of disease progression, with radical cystectomy delays beyond 12 wk from diagnosis or completion of neoadjuvant chemotherapy. Prioritization of these patients for surgery or management with radiochemotherapy is encouraged. Active surveillance should be used for low-risk prostate cancer (PCa). Treatment of most patients with intermediate- and high-risk PCa can be deferred 3–6 mo without change in outcomes. The same may be true for cancers with the highest risk of progression. With radiotherapy, neoadjuvant androgen deprivation therapy (ADT) is the standard of care. For surgery, although the added value of neoadjuvant ADT is questionable, it may be considered if a patient is interested in such an approach. Intervention may be safely deferred for T1/T2 renal masses, while locally advanced renal tumors (≥T3) should be treated expeditiously. Patients with metastatic renal cancer may consider vascular endothelial growth factor targeted therapy over immunotherapy. Risks for delay in the treatment of upper tract urothelial cancer depend on grade and stage. For patients with high-grade disease, delays of 12 wk in nephroureterectomy are not associated with adverse survival outcomes. Expert guidance recommends expedient local treatment of testis cancer. In penile cancer, adverse outcomes have been observed with delays of ≥3 mo before inguinal lymphadenectomy. Limitations include a paucity of data and methodologic variations for many cancers. Conclusions Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system. Patient summary The coronavirus disease 2019 pandemic has led to delays in the treatment of patients with urologic malignancies. Based on a review of the literature, patients with high-grade urothelial carcinoma, advanced kidney cancer, testicular cancer, and penile cancer should be prioritized for treatment during these challenging times.
has issue date	2020-05-03(xsd:dateTime)
bibo:doi	10.1016/j.eururo.2020.04.063
bibo:pmid	32414626
has license	els-covid
sha1sum (hex)	1e9b5810fa67ca4efa2b5c5ac1d80497b7b9b6d2
schema:url	https://doi.org/10.1016/j.eururo.2020.04.063
resource representing a document's title	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic
has PubMed Central identifier	PMC7196384
has PubMed identifier	32414626
schema:publication	Eur Urol
resource representing a document's body	covid:1e9b5810fa67ca4efa2b5c5ac1d80497b7b9b6d2#body_text
is schema:about of	named entity 'cancers' named entity 'Collaborative' named entity 'CONTEXT' named entity 'coronavirus disease 2019' named entity 'pandemic' named entity 'Genitourinary' named entity 'coronavirus disease 2019' named entity 'Triage' named entity 'Cancers' named entity 'Genitourinary' named entity 'COVID-19 Pandemic' named entity 'hematuria' named entity 'prognosis' named entity 'disease recurrence' named entity 'gemcitabine' named entity 'immunosuppression' named entity 'kidney cancer' named entity 'health care' named entity 'metastases' named entity 'Clinical trials' named entity '19, 20' named entity 'VEGF' named entity 'COVID-19 pandemic' named entity 'germ cell tumors' named entity 'chemotherapy' named entity 'biopsy' named entity 'renal function' named entity 'malignancy' named entity 'Nephrectomy' named entity 'significant difference' named entity 'thrombus' named entity 'COVID' named entity 'metastases' named entity 'targeted therapies' named entity 'metastatic' named entity 'BCG' named entity 'muscle' named entity 'orchiectomy' named entity 'lympho' named entity 'histology' named entity 'lesion' named entity 'metastatic' named entity 'phenotype' named entity 'metastatic' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'PubMed' named entity 'CSS' named entity 'neoadjuvant' named entity 'targeted therapies' named entity 'metastatic' named entity 'prostate cancer' named entity 'UTUC' named entity 'cumulative incidence' named entity 'long-term' named entity 'neoadjuvant' named entity 'doxorubicin' named entity 'COVID-19 pandemic' named entity 'logistic regression' named entity 'systemic therapy' named entity 'endoscopic' named entity 'infection' named entity 'tumors' named entity 'cystoscopy' named entity 'oncologic' named entity 'upper tract' named entity 'first-line therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software